Stay updated on KSI-301 vs Aflibercept in Wet AMD Clinical Trial
Sign up to get notified when there's something new on the KSI-301 vs Aflibercept in Wet AMD Clinical Trial page.
Latest updates to the KSI-301 vs Aflibercept in Wet AMD Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No study content or user-facing information appears to be changed.SummaryDifference0.0%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA new 'Locations' section with state listings was added; individual state location subsections and the HHS Vulnerability Disclosure section were removed.SummaryDifference2%
- Check54 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.2.0 has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check61 days agoChange DetectedThe funding-status notice and its operating-status guidance have been removed from the page.SummaryDifference0.2%
- Check75 days agoChange DetectedNo substantive content changes detected; the page sections such as Overview, Eligibility Criteria, Plan, and Locations appear the same, with only minor visual or formatting differences. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check104 days agoChange DetectedCore content updated: a government funding and operating status notice has been added and the version updated to v3.2.0; the prior v3.1.0 tag was removed.SummaryDifference3%
Stay in the know with updates to KSI-301 vs Aflibercept in Wet AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KSI-301 vs Aflibercept in Wet AMD Clinical Trial page.